Naltrexone (Vivitrol)
Small molecule
Evidence outlook
Approved: Opioid and Alcohol Dependence
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01218958 NCT01218958 · Alcoholism This was a large, randomized, quadruple-blind, placebo-controlled trial with a validated clinical drinking-behavior endpoint. The primary results were mixed: 380 mg significantly reduced heavy-drinking days versus placebo, but 190 mg did not, so the overall evidence is limited despite the strong trial design. Registry: NCT01218958 | 3 | Percentage of Heavy Drinking Days Over the Treatment Period (Baseline through Week 24 (168 days)) 2003-09 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (3)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2/3 (1)
What this study did
Competitive landscape
Other Opioid receptor drugs
nalmefene nasal spray, Naloxone (Narcan), Naltrexone/Acetaminophen (ALLOD-2). Compare all 4 Opioid receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Opioid and Alcohol Dependence: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Naltrexone (Vivitrol): this drug | Approved | Small molecule | Opioid receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Nalmefene Nasal Spray (OPVEE) | Approved(overall) | Small molecule | Opioid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Naloxone (Narcan) | Approved(overall) | Small molecule | Opioid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Naltrexone | Approved | Small molecule | Opioid receptors (mu-opioid receptor) | not yet graded | No reviewed efficacy summary in this indication | |
| Naltrexone / Acetaminophen (ALLOD-2) | Phase 2/3(overall) | — | Opioid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Naltrexone (Vivitrol) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.